Francesca Raffaelli

Francesca Raffaelli

Auto-generated profile, based on publicly available information

Francesca Raffaelli


Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 June 2018 in Clinical Infectious Diseases
Verified
Journal Article
Closed access
MTMario Tumbarello
Mario Tumbarello
ETEnrico Maria Trecarichi
Enrico Maria Trecarichi
Alberto CoronaAlberto Corona
Alberto Corona
FRFrancesco Giuseppe De Rosa
Francesco Giuseppe De Rosa
MBMatteo Bassetti
Matteo Bassetti
PVPierluigi Viale
Pierluigi Viale
Ceftazidime-avibactam (CAZ-AVI) has been approved in Europe for the treatment of complicated intra-abdominal and urinary tract infections, as well as hospital-acquired pneumonia, and for gram-negative infections with limited treatment options. CAZ-AVI displays in vitro activity against Klebsiella pneumoniae carbapenemase (KPC) enzyme producers, but clinical trial data on its efficacy in this setting are lacking. We retrospectively reviewed 138 cases of infections caused by KPC-producing K. pneumoniae (KPC-Kp) in adults who received CAZ-AVI in compassionate-use programs in Italy. Case features and outcomes were analyzed, and survival was then specifically explored in the large subcohort whose infections were bacteremic. The 138 patients started CAZ-AVI salvage therapy after a first-line treatment (median, 7 days) with other antimicrobials. CAZ-AVI was administered with at least 1 other active antibiotic in 109 (78.9%) cases. Thirty days after infection onset, 47 (34.1%) of the 138 patients had died. Thirty-day mortality among the 104 patients with bacteremic KPC-Kp infections was significantly lower than that of a matched cohort whose KPC-Kp bacteremia had been treated with drugs other than CAZ-AVI (36.5% vs 55.8%, P = .005). Multivariate analysis of the 208 cases of KPC-Kp bacteremia identified septic shock, neutropenia, Charlson comorbidity index ≥3, and recent mechanical ventilation as independent predictors of mortality, whereas receipt of CAZ-AVI was the sole independent predictor of survival. CAZ-AVI appears to be a promising drug for treatment of severe KPC-Kp infections, especially those involving bacteremia.

1 January 2020
Verified
Journal Article
Closed access
Danilo BuonsensoDanilo Buonsenso
Danilo Buonsenso
APA. Piano
A. Piano
FRF. Raffaelli
F. Raffaelli
NBN. Bonadia
N. Bonadia
KDK. de Gaetano Donati
K. de Gaetano Donati
FFF. Franceschi
F. Franceschi

1 April 2019 in International Journal of Antimicrobial Agents
Verified
Journal Article
Closed access
MBMatteo Bassetti
Matteo Bassetti
NCNadia Castaldo
Nadia Castaldo
ACANNA MARIA CATTELAN
ANNA MARIA CATTELAN
CMCristina Mussini
Cristina Mussini
ERElda Righi
Elda Righi
EMEmanuele Malfatto
Emanuele Malfatto

26 April 2022 in Antibiotics
Verified
Journal Article
Open access
PDF file
ALAngela Raffaella Losito
Angela Raffaella Losito
FRFrancesca Raffaelli
Francesca Raffaelli
PGPaola Del Giacomo
Paola Del Giacomo
MTMario Tumbarello
Mario Tumbarello
P. aeruginosa is still one of the most threatening pathogens responsible for serious hospital-acquired infections. It is intrinsically resistant to many antimicrobial agents and additional acquired resistance further complicates the management of such infections. High rates of combined antimicrobial resistance persist in many countries, especially in the eastern and south-eastern parts of Europe. The aim of this narrative review is to provide a comprehensive assessment of the epidemiology, latest data, and clinical evidence on the current and new available drugs active against P. aeruginosa isolates with limited treatment options. The latest evidence and recommendations supporting the use of ceftolozane-tazobactam and ceftazidime-avibactam, characterized by targeted clinical activity against a significant proportion of P. aeruginosa strains with limited treatment options, are described based on a review of the latest microbiological and clinical studies. Cefiderocol, with excellent in vitro activity against P. aeruginosa isolates, good stability to all β-lactamases and against porin and efflux pumps mutations, is also examined. New carbapenem combinations are explored, reviewing the latest experimental and initial clinical evidence. One section is devoted to a review of new anti-pseudomonal antibiotics in the pipeline, such as cefepime-taniborbactam and cefepime-zidebactam. Finally, other “old” antimicrobials, mainly fosfomycin, that can be used as combination strategies, are described.

1 June 2014 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
PDF file
MTMario Tumbarello
Mario Tumbarello
ETEnrico Maria Trecarichi
Enrico Maria Trecarichi
FTFabio Tumietto
Fabio Tumietto
VBValerio Del Bono
Valerio Del Bono
FRFrancesco Giuseppe De Rosa
Francesco Giuseppe De Rosa
PVPierluigi Viale
Pierluigi Viale
The production of Klebsiella pneumoniae carbapenemases (KPCs) by Enterobacteriaceae has become a significant problem in recent years. To identify factors that could predict isolation of KPC-producing K. pneumoniae (KPCKP) in clinical samples from hospitalized patients, we conducted a retrospective, matched (1:2) case-control study in five large Italian hospitals. The case cohort consisted of adult inpatients whose hospital stay included at least one documented isolation of a KPCKP strain from a clinical specimen. For each case enrolled, we randomly selected two matched controls with no KPCKP-positive cultures of any type during their hospitalization. Matching involved hospital, ward, and month/year of admission, as well as time at risk for KPCKP isolation. A subgroup analysis was also carried out to identify risk factors specifically associated with true KPCKP infection. During the study period, KPCKP was isolated from clinical samples of 657 patients; 426 of these cases appeared to be true infections. Independent predictors of KPCKP isolation were recent admission to an intensive care unit (ICU), indwelling urinary catheter, central venous catheter (CVC), and/or surgical drain, ≥2 recent hospitalizations, hematological cancer, and recent fluoroquinolone and/or carbapenem therapy. A Charlson index of ≥3, indwelling CVC, recent surgery, neutropenia, ≥2 recent hospitalizations, and recent fluoroquinolone and/or carbapenem therapy were independent risk factors for KPCKP infection. Models developed to predict KPCKP isolation and KPCKP infection displayed good predictive power, with the areas under the receiver-operating characteristic curves of 0.82 (95% confidence interval [CI], 0.80 to 0.84) and 0.82 (95% CI, 0.80 to 0.85), respectively. This study provides novel information which might be useful for the clinical management of patients harboring KPCKP and for controlling the spread of this organism.

1 February 2018 in International Journal of Antimicrobial Agents
Verified
Journal Article
Closed access
Maddalena GiannellaMaddalena Giannella
Maddalena Giannella
ETEnrico Maria Trecarichi
Enrico Maria Trecarichi
Daniele Roberto GiacobbeDaniele Roberto Giacobbe
Daniele Roberto Giacobbe
FRFrancesco Giuseppe De Rosa
Francesco Giuseppe De Rosa
MBMatteo Bassetti
Matteo Bassetti
MTMario Tumbarello
Mario Tumbarello